Rxivist logo

Assessing the in vitro resistance development in Enterovirus 71 in the context of combination antiviral treatment

By Kristina Lanko, Chenyan Shi, Shivaprasad Patil, Leen Delang, Jelle Matthijnssens, Carmen Mirabelli, Johan Neyts

Posted 10 Feb 2020
bioRxiv DOI: 10.1101/2020.02.10.935536

There are currently no antivirals available to treat infection with enterovirus A71 (EV-A71) or any other enterovirus. The extensively studied capsid binders select rapidly for drug-resistant variants. We here explore whether the combination of two direct-acting enterovirus inhibitors with a different mechanism of action may delay or prevent resistance development to the capsid binders. To that end, the in vitro dynamics of resistance development to the capsid binder pirodavir was studied either alone or in combination with (i) a viral 2C-targeting compound (SMSK_0213), (ii) a viral 3C-protease inhibitor (rupintrivir) or (iii) a viral RNA-dependent RNA polymerase (RdRp) inhibitor [7-deaza-2C-methyladenosine (7DMA)]. We demonstrate that combining pirodavir with either rupintrivir or the nucleoside analogue 7DMA delays the development of resistance to pirodavir and that no resistance to the protease or polymerase inhibitor develops. The combination of pirodavir with the 2C inhibitor results in a double-resistant virus population. The deep sequencing analysis of resistant populations revealed that even though resistant mutations are present in less than 30% of the population, this still provides the resistant phenotype.

Download data

  • Downloaded 177 times
  • Download rankings, all-time:
    • Site-wide: 96,048 out of 119,012
    • In microbiology: 7,166 out of 9,401
  • Year to date:
    • Site-wide: 49,526 out of 119,012
  • Since beginning of last month:
    • Site-wide: 58,074 out of 119,012

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)